AnaptysBio, Inc. (ANAB) NASDAQ
66.96
-0.4(-0.59%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
66.96
-0.4(-0.59%)
Currency In USD
| Previous Close | 67.36 |
| Open | 65.49 |
| Day High | 68.69 |
| Day Low | 62.07 |
| 52-Week High | 72.36 |
| 52-Week Low | 11.4 |
| Volume | 1.27M |
| Average Volume | 859,484 |
| Market Cap | 2.89B |
| PE | -145.57 |
| EPS | -0.46 |
| Moving Average 50 Days | 47.21 |
| Moving Average 200 Days | 29.83 |
| Change | -0.4 |
Anaptys Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 9:15 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc.
Jan 08, 2026 11:00 PM GMT
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovativ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o